Study of a new drug for advanced prostate cancer that has spread and progressed
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug called JNJ-98768111 in people with advanced prostate cancer that has spread and is no longer responding to current hormone-based treatments. It aims to see if the drug is safe and effective, and participants will receive the study drug while continuing some standard hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer must be confirmed by biopsy (adenocarcinoma) and have spread to other parts of the body.
- You must have received at least one prior treatment that targets androgen receptors (like enzalutamide or apalutamide).
- Your PSA level must be 2 ng/mL or higher.
- You must have had your testicles removed or be on ongoing hormone therapy (ADT) to lower testosterone.
- Your cancer must be progressing based on PSA, scans, or bone lesions, and you must have a good performance status (ECOG 0 or 1).
- You must agree to use highly effective contraception and not donate sperm during the trial and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
This trial tests a new combination of two drugs, pasritamig and JNJ-86974680, for men with a certain type of advanced prostate cancer that has spread to bone or lymph nodes but not to organs like the lungs or liver. It aims to see if this combination is safe and effective.
This trial tests an experimental drug (JNJ-101556143) for men with metastatic prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can slow down or stop the cancer from growing.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
This trial tests a new drug called JNJ-89862175 for people with certain advanced solid tumors, including lung adenocarcinoma, kidney cancer, ovarian cancer, and uterine cancer. The goal is to see if this treatment is safe and effective.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.